Compare Abbott Laboratories (ABT) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Suncor Energy Inc. — how do they compare? Abbott Laboratories trades at $109.55 (market cap $187.95B), while Suncor Energy Inc. trades at $63.2 (market cap $73.34B). The key difference: Abbott Laboratories is far larger — about 2.6× Suncor Energy Inc.'s market cap, and Suncor Energy Inc. pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABT | SU | |
|---|---|---|
Market Cap | $187.95B | $73.34B |
Sector | Health | Energy |
52-Week High | $136.62 | $69.73 |
52-Week Low | $82.57 | $38.17 |
Enterprise Value | $214.96B | $80.01B |
Dividend Yield | 2.32% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Suncor Energy (SU) trades at $60.1, down 2.04% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.27, beating estimates, and maintains a strong balance sheet with $3.48B in cash. Valuation ratios appear attractive with a P/E of 11.24 and EV/EBITDA of 5.42. Recent news highlights leadership changes, with Peter Zebedee set to become CEO in 2027.
Outlook is mixed: strong cash flow and analyst buy ratings (74% consensus) support upside, but near-term technical weakness and operational challenges from weather impacts pose risks. The stock offers value with solid profitability (ROE 19.25%) but faces volatility from oil price fluctuations and execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
